UNSPSC 51151528: Quilostigmine

This classification denotes an acetylcholinesterase inhibitor with the molecular formula C23H27N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2L1YNO4SQJ, chemically known as 2(1h)-isoquinolinecarboxylic acid, 3,4-dihydro-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3as-cis)- but generally known as quilostigmine, which bears US NIH Compound Identifier 132228. European Medicines Agency schedules Quilostigmine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10196MIG.

UNSPSC 51151528 Quilostigmine is a Commodity code that encompasses pharmaceutical products and related health-intervention supplies, though recent state and local solicitations under this code show a mismatch with the nominally narrow scope. The only recent opportunities tagged to this code involve naloxone and drug deactivation systems for community health programs, and an exploratory Request for Information on direct-to-manufacturer prescription fulfillment—neither of which aligns with quilostigmine (a cholinesterase inhibitor used in Alzheimer's treatment). State and local buyers using this code classification are primarily county health departments and state health agencies, with Seminole County, Florida and the Texas Health and Human Services Commission both active in recent postings. The actual work being solicited includes procurement of emergency medical supplies (naloxone kits and deactivation equipment) and strategic pharmacy benefit consulting aimed at reducing prescription fulfillment costs through direct manufacturer relationships outside traditional pharmacy benefit manager channels.

Seminole County, Florida posted an Invitation for Bids (IFB 60459723LAS) on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; the response deadline was July 26, 2023. The Texas Health and Human Services Commission issued a Request for Information (RFI HHS0017013) on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer program targeting negotiated net pricing and outcomes-based contracting models. Activity under this code appears concentrated in Florida and Texas, with no additional recent opportunities identified in the source material. The code shows limited current procurement velocity, and vendors should note the significant gap between the nominal commodity name (quilostigmine) and the health-system procurement it actually tags—suggesting either data classification error at the issuing-body level or that this code serves as a broader catch-all for pharmaceutical and pharmacy-related state and local purchases.